Landmark HIFI-2 Study Shows 71% ADT-Free Survival for EDAP's Focal One® in Recurrent Prostate Cancer
Summary
EDAP TMS announced the publication of positive HIFI-2 study data for its Focal One® Robotic HIFU system in treating radiorecurrent prostate cancer. The large, prospective, nationwide trial demonstrated a 71% androgen deprivation therapy-free survival rate at 30 months, with up to 84% in favorable patient subgroups, alongside an acceptable safety profile and preserved quality of life. This 'landmark' data provides compelling clinical evidence, reinforcing Focal One® as a viable, organ-preserving treatment option in a patient population with limited alternatives. This positive product development is particularly significant for EDAP, a small-cap company, especially following its recent disclosure of a 'going concern' warning and debt covenant breach in its March 25, 2026 10-K filing. The strong clinical validation could be crucial for driving increased adoption, market share, and reimbursement, which are vital for the company's long-term financial health and investor confidence. Traders will be watching for the impact of this data on future sales and the company's ability to address its financial challenges.
At the time of this announcement, EDAP was trading at $3.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $124.1M. The 52-week trading range was $1.21 to $5.05. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.